Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

15 Jan 2014 07:00

RNS Number : 6625X
Plant Health Care PLC
15 January 2014
 

 

15 January 2014

 

 

 

 

Plant Health Care plc

 

("Plant Health Care" or "the Company")

 

Trading Update

 

 

Plant Health Care plc, ("PHC"), a leading provider of novel patent-protected biological products to the global agriculture markets, provides the following update for the 12 months to 31 December 2013 ahead of its full year results announcement on 24 March 2014.

 

Trading continues to be in line with the Board's expectations. The full year results will reflect the implementation of the new strategy that was announced following the US$20 million fundraising completed in April 2013.

 

In September's interim results statement, PHC reported significant progress, most notably:

 

· New management in place in new headquarters in Raleigh, North Carolina

· New Development and Commercial agreements with Arysta LifeScience and others

· Moved to expanded research facilities in Seattle which enhanced and accelerated investment in the discovery and evaluation of a new generation of Harpin products

 

In the second half of the year, implementation of the new strategy has continued:

 

· In July, the Company's agreement with Monsanto was discontinued and PHC recovered its globally licensed rights to Harpin as a seed treatment.

· In September, Jeff Hovey was appointed Chief Financial Officer. Since joining, he has completed the transfer of the Company's administration and accounting functions from Pittsburgh to Raleigh. The Pittsburgh office was closed on 31 December 2013.

· In November, PHC completed the sale of its non-core European distribution activities while retaining a core capability in the UK and Spain to enable the continued exploitation of Europe, South Africa and certain other non-American markets.

 

All of these actions have been achieved in line with the targets set out at the time of the fundraising.

 

The full year results will reflect these changes and will set out the contribution from our continuing activities and those relating to discontinued and non-core activities.

 

~ ENDS ~

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer

Tel: +1 919 926 1600

Liberum Capital - Nomad and Broker

Clayton Bush / Thomas Bective

Tel: +44 (0) 20 3100 2222

Powerscourt

Sophie Moate / Nick Dibden

Tel: +44 (0) 20 7250 1446

 

About Plant Health Care plc: Plant Health Care is a leading provider of patent protected biological products aimed at the agriculture industry that are environmentally beneficial. Through the commercialisation of these products, Plant Health Care is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management.

 

Further information is available at: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFSALLISLIS
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.